Disease-modifying therapies for multiple sclerosis

BMJ. 2018 Nov 27:363:k4674. doi: 10.1136/bmj.k4674.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cost-Benefit Analysis
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Practice Guidelines as Topic

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents